TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$3.80 USD
0.00 (0.00%)
Updated Jun 7, 2024 03:47 PM ET
After-Market: $3.75 -0.05 (-1.32%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[TBIO]
Reports for Purchase
Showing records 81 - 100 ( 108 total )
Industry: Medical - Drugs
We May Be Getting There - Reiterate Buy $25 PT
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Industry: Medical - Drugs
Getting Through the Mucus In Cystic Fibrosis Patients
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
OTC Program Moves Ahead - Another Shot on Goal. Reiterate Buy.
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
We are initiating with a Buy rating and a $25PT
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
MRT5005 Progress in CF With Data on Deck This Year; Reit Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
Encouraging Preclinical Data for MRT5201 Observed for OTC Deficiency
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
Confidence in mRNA Therapeutics Platform Despite IND Headwinds; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
Await Further Clarity Surrounding OTCD Clinical Hold
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
Believe Yesterday''s Announcements Were Important and Set Stage for Future Inflection Points; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
Believe Success From Either Program May Be Highly Translatable Across MRT Platform; Initiating With Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Transgenomic, Inc.
Industry: Medical - Instruments
Company: Transgenomic, Inc.
Industry: Medical - Instruments
Company: Transgenomic, Inc.
Industry: Medical - Instruments
Due to a reallocation of resources in our research group, we are suspending coverage on Transgenomic, Inc.
Provider: Griffin Securities, Inc.